MA34768B1 - Comprimé orodispersible - Google Patents

Comprimé orodispersible

Info

Publication number
MA34768B1
MA34768B1 MA36063A MA36063A MA34768B1 MA 34768 B1 MA34768 B1 MA 34768B1 MA 36063 A MA36063 A MA 36063A MA 36063 A MA36063 A MA 36063A MA 34768 B1 MA34768 B1 MA 34768B1
Authority
MA
Morocco
Prior art keywords
active ingredient
pharmaceutically active
lansoprazole
pellets
copolymer
Prior art date
Application number
MA36063A
Other languages
English (en)
Inventor
Shiro Ishii
Yutaka Ebisawa
Takayuki Okabe
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45509604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34768(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA34768B1 publication Critical patent/MA34768B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE UN COMPRIMÉ ORODISPERSIBLE OBTENU PAR COMPRESSION DE GRANULÉS FINS PRÉSENTANT UNE LIBÉRATION CONTRÔLÉE DE LANSOPRAZOLE ET D'UN ADDITIF, PERMETTANT DE SUPPRIMER LA RUPTURE DES GRANULÉS FINS PENDANT LA FORMATION DE COMPRIMÉS ET DE CONTRÔLER LA LIBÉRATION DE LANSOPRAZOLE SUR UNE LONGUE DURÉE, ET POUVANT MAINTENIR UNE CONCENTRATION THÉRAPEUTIQUEMENT EFFICACE PENDANT UNE DURÉE PROLONGÉE, ET PRÉSENTANT UNE MEILLEURE PROPRIÉTÉ DE DISPERSION DANS LA CAVITÉ BUCCALE. LE COMPRIMÉ ORODISPERSIBLE SELON L'INVENTION COMPREND : (I) DES GRANULÉS FINS PRÉSENTANT UNE LIBÉRATION CONTRÔLÉE D'UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF CONTENANT DES GRANULÉS FINS RENFERMANT UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF ET UNE COUCHE D'ENROBAGE CONTENANT UN COPOLYMÈRE ACIDE MÉTHACRYLIQUE/ACRYLATE DE MÉTHYLE/¨MÉTHACRYLATE DE MÉTHYLE, LES GRANULÉS FINS QUI RENFERMENT UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF ÉTANT ENROBÉS D'UNE QUANTITÉ SUPÉRIEURE À 80 % EN POIDS ET NE DÉPASSANT PAS 300 % EN POIDS DUDIT COPOLYMÈRE, ET (II) DES GRANULÉS FINS PRÉSENTANT UNE LIBÉRATION CONTRÔLÉE D'UN INGRÉDIENT PHARMACEUTIQUEMENT ACTIF QUI COMPORTE L'INGRÉDIENT PHARMACEUTIQUEMENT ACTIF ET UNE COUCHE D'ENROBAGE COMPRENANT (A) UN COPOLYMÈRE ACRYLATE D'ÉTHYLE/MÉTHACRYLATE DE MÉTHYLE ET (B) UN OU PLUSIEURS TYPES DE POLYMÈRES SÉLECTIONNÉS DANS LE GROUPE COMPRENANT LES ÉLÉMENTS : COPOLYMÈRE ACIDE MÉTHACRYLIQUE/ACRYLATE D'ÉTHYLE, PHTALATE HYPROMELLOSE, CARBOXYMÉTHYLÉTHYLCELLULOSE, PHTALATE ACÉTATE POLYVINYLIQUE, SUCCINATE ACÉTATE MÉTHYLCELLULOSE D'HYDROXYPROPYLE ET PHTALATE ACÉTATE DE CELLULOSE. LES GRANULÉS FINS (I) ET LES GRANULÉS FINS (II) PRÉSENTENT UNE GRANULOMÉTRIE MOYENNE NE DÉPASSANT PAS 500 MICROMÈTRES, ET L'INGRÉDIENT PHARMACEUTIQUEMENT ACTIF EST DU LANSOPRAZOLE OU UNE FORME OPTIQUEMENT ACTIVE DU LANSOPRAZOLE OU ENCORE UN SEL DU LANSOPRAZOLE.
MA36063A 2010-12-27 2013-06-28 Comprimé orodispersible MA34768B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061427384P 2010-12-27 2010-12-27
PCT/JP2011/080568 WO2012091153A2 (fr) 2010-12-27 2011-12-26 Comprimé orodispersible

Publications (1)

Publication Number Publication Date
MA34768B1 true MA34768B1 (fr) 2013-12-03

Family

ID=45509604

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36063A MA34768B1 (fr) 2010-12-27 2013-06-28 Comprimé orodispersible

Country Status (24)

Country Link
US (1) US20130273157A1 (fr)
EP (1) EP2658530A2 (fr)
JP (1) JP2014501224A (fr)
KR (1) KR20140007364A (fr)
CN (1) CN103402500A (fr)
AR (1) AR084610A1 (fr)
AU (1) AU2011350396A1 (fr)
BR (1) BR112013014875A2 (fr)
CA (1) CA2823166C (fr)
CL (1) CL2013001793A1 (fr)
CO (1) CO6731132A2 (fr)
CR (1) CR20130327A (fr)
EA (1) EA028217B1 (fr)
EC (1) ECSP13012718A (fr)
MA (1) MA34768B1 (fr)
MX (1) MX2013007588A (fr)
PE (1) PE20141115A1 (fr)
PH (1) PH12013501391A1 (fr)
SG (2) SG10201602311XA (fr)
TN (1) TN2013000220A1 (fr)
TW (1) TW201304823A (fr)
UY (1) UY33841A (fr)
WO (1) WO2012091153A2 (fr)
ZA (1) ZA201304617B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2717947C (fr) 2008-03-11 2020-07-07 Takeda Pharmaceutical Company Limited Preparation solide orodispersible
WO2013102145A1 (fr) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Composés d'aldéhydes hétéroaryles substitués et leurs procédés d'utilisation dans l'accroissement de l'oxygénation tissulaire
DK3738434T3 (da) 2011-12-28 2023-12-04 Global Blood Therapeutics Inc Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering
GB201303781D0 (en) 2013-03-04 2013-04-17 Gauthier Pierre Pascal Oral timer device and method of using same
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SI3102208T2 (sl) 2014-02-07 2024-10-30 Global Blood Therapeutics, Inc. Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
SG10201912713YA (en) 2014-11-14 2020-02-27 Gemphire Therapeutics Inc PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI778983B (zh) * 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CA3059073A1 (fr) 2017-04-18 2018-10-25 Gemphire Therapeutics Inc. Gemcabene, sels pharmaceutiquement acceptables de celui-ci, compositions de celui-ci et procedes d'utilisation de celui-ci
US20190008779A1 (en) * 2017-05-11 2019-01-10 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
JP7228535B2 (ja) 2017-07-10 2023-02-24 武田薬品工業株式会社 ボノプラザン含有製剤
CN108576205B (zh) * 2018-03-22 2022-01-04 湖北省农业科学院农产品加工与核农技术研究所 一种草莓联合干燥的处理方法
EP3860975B1 (fr) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulateurs de l'hémoglobine pour le traitement de la drépanocytose

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
EP0553777B1 (fr) 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Comprimé à dissolution rapide et sa fabrication
JP2919771B2 (ja) 1995-04-17 1999-07-19 佐藤製薬株式会社 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤
JPH0948726A (ja) 1995-08-07 1997-02-18 Tanabe Seiyaku Co Ltd 口腔内速崩壊性製剤およびその製法
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
KR100554924B1 (ko) 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
KR100536783B1 (ko) 1998-07-28 2005-12-14 다케다 야쿠힌 고교 가부시키가이샤 급속 붕해성 고체 제제
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CN1193024C (zh) 2000-04-28 2005-03-16 武田药品工业株式会社 生产旋光的亚砜衍生物的方法
EP1293507B1 (fr) 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Procede de production d'un cristal
KR20100002278A (ko) 2000-12-01 2010-01-06 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
CA2630235A1 (fr) * 2005-12-20 2007-07-12 Teva Pharmaceutical Industries Ltd. Comprimes a desintegration orale de lansoprazole
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1837016A3 (fr) * 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique en multiple-unité
JP5366558B2 (ja) * 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
CA2717947C (fr) * 2008-03-11 2020-07-07 Takeda Pharmaceutical Company Limited Preparation solide orodispersible
US20100015239A1 (en) * 2008-07-17 2010-01-21 Ahmed Salah U Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same

Also Published As

Publication number Publication date
ZA201304617B (en) 2014-08-27
AR084610A1 (es) 2013-05-29
JP2014501224A (ja) 2014-01-20
PE20141115A1 (es) 2014-09-12
AU2011350396A1 (en) 2013-07-11
CL2013001793A1 (es) 2013-12-06
TW201304823A (zh) 2013-02-01
SG10201602311XA (en) 2016-04-28
WO2012091153A2 (fr) 2012-07-05
CR20130327A (es) 2013-08-22
EP2658530A2 (fr) 2013-11-06
KR20140007364A (ko) 2014-01-17
EA201390981A1 (ru) 2014-07-30
MX2013007588A (es) 2013-08-09
BR112013014875A2 (pt) 2016-10-18
CA2823166C (fr) 2019-04-09
US20130273157A1 (en) 2013-10-17
WO2012091153A3 (fr) 2012-09-07
ECSP13012718A (es) 2013-12-31
TN2013000220A1 (en) 2014-11-10
CN103402500A (zh) 2013-11-20
UY33841A (es) 2012-07-31
EA028217B1 (ru) 2017-10-31
PH12013501391A1 (en) 2013-08-28
CO6731132A2 (es) 2013-08-15
SG190905A1 (en) 2013-07-31
CA2823166A1 (fr) 2012-07-05

Similar Documents

Publication Publication Date Title
TN2013000220A1 (en) Orally disintegrating tablet
CA2463134C (fr) Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
CN1678295A (zh) 可延长释放低溶解度活性成分的多微囊形式的口服药物制剂
RU2013141534A (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
JP2016532655A5 (fr)
RU2014114541A (ru) Полоска для отбеливания зубов
JP2008534530A (ja) 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形
NZ605601A (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
MA32174B1 (fr) Preparation solide orodispersible
JP2016172752A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用の方法
TW200635617A (en) Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form
JP2008522989A5 (fr)
US8563035B2 (en) Oral tablet compositions of dexlansoprazole
MX2024010009A (es) Formas de dosificacion oral de agonista de tr\03b2 vk2809 para el tratamiento de trastornos hepaticos y metodos de preparacion de las mismas.
RU2018111690A (ru) Пероральная лекарственная форма будесонида
CN107661326A (zh) 用于遗尿的药物制剂及其使用方法
AR071970A1 (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
WO1999059557A1 (fr) Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation
WO2007025182A3 (fr) Compositions de medicament renfermant des matrices d'hypermellose a liberation commandee
AU2011274851A1 (en) Particle coating preparation
FR2885526A1 (fr) Medicament oral a base d'inhibiteur de pompe a protons
HRP20221162T1 (hr) Pelete s višeslojnom strukturom, namijenjene odgođenom otpuštanju aktivne tvari u distalnom debelom crijevu
CA2491172C (fr) Microcapsules pour la liberation retardee et controlee du perindopril
RU2017121505A (ru) Композиция цефподоксима проксетила с пролонгированным высвобождением
EP2682112A1 (fr) Formulations de capsule combinée de flurbiprofène et famotidine